Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127564261 | 12756426 | 1 | I | 2004 | 20160908 | 20160916 | 20160916 | EXP | BE-ASTRAZENECA-2016SE97339 | ASTRAZENECA | 45.00 | YR | F | Y | 0.00000 | 20160917 | BE | BE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127564261 | 12756426 | 1 | PS | ZOLADEX | GOSERELIN ACETATE | 1 | Subcutaneous | U | U | 19726 | IMPLANT | ||||||||
| 127564261 | 12756426 | 2 | SS | TAMOXIFEN | TAMOXIFEN | 1 | Oral | U | U | 0 | TABLET | ||||||||
| 127564261 | 12756426 | 3 | SS | TAMOXIFEN | TAMOXIFEN | 1 | Oral | U | U | 0 | TABLET | ||||||||
| 127564261 | 12756426 | 4 | C | LETROZOLE. | LETROZOLE | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 5 | C | CHEMOTHERAPY | UNSPECIFIED INGREDIENT | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 6 | C | ADRIAMYCIN | DOXORUBICIN HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 7 | C | RADIATION THERAPY | RADIATION THERAPY | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 8 | C | PALBOCICLIB | PALBOCICLIB | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 9 | C | TAXOL | PACLITAXEL | 1 | WEEKLY | 0 | |||||||||||
| 127564261 | 12756426 | 10 | C | CAPECITABINE. | CAPECITABINE | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 11 | C | ERIBULINE | ERIBULIN | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 12 | C | CAELYX | DOXORUBICIN HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 13 | C | CARBOPLATIN. | CARBOPLATIN | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 14 | C | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 15 | C | NAVELBINE | VINORELBINE TARTRATE | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 16 | C | AFINITOR | EVEROLIMUS | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 17 | C | ENDOXAN | CYCLOPHOSPHAMIDE | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 18 | C | CISPLATINE | CISPLATIN | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 19 | C | CELLTOP | ETOPOSIDE | 1 | 0 | ||||||||||||
| 127564261 | 12756426 | 20 | C | DOCETAXEL. | DOCETAXEL | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127564261 | 12756426 | 1 | Metastases to ovary |
| 127564261 | 12756426 | 2 | Breast cancer |
| 127564261 | 12756426 | 3 | Breast cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127564261 | 12756426 | OT |
| 127564261 | 12756426 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127564261 | 12756426 | Febrile neutropenia | |
| 127564261 | 12756426 | Liver disorder | |
| 127564261 | 12756426 | Malignant neoplasm progression | |
| 127564261 | 12756426 | Metastases to bone | |
| 127564261 | 12756426 | Metastases to bone marrow | |
| 127564261 | 12756426 | Metastases to liver | |
| 127564261 | 12756426 | Metastases to lung | |
| 127564261 | 12756426 | Metastases to lymph nodes | |
| 127564261 | 12756426 | Metastases to ovary | |
| 127564261 | 12756426 | Neurotoxicity |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127564261 | 12756426 | 1 | 2004 | 0 | ||
| 127564261 | 12756426 | 2 | 2000 | 2001 | 0 | |
| 127564261 | 12756426 | 4 | 2004 | 0 |